Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
845
datasets available to search
ShareScore release 0.9.0
Dataset results
845 results for “Inflammatory bowel disease”
Therapeutic dosage of inflammatory bowel disease drugs
<p>Therapeutic doses of inflammatory bowel disease drugs in adults and in pediatrics.</p> <p>More data specific to these drugs can be found at www.ibd-eii.com</p>
Assessing the Drug Exposure Risk of Infants Breastfed by Women With Inflammatory Bowel Disease
ClinicalTrials.gov study NCT03397108. IPD Sharing: YES. Countries: 1. Publications: 2.
Healthcare Resource Utilisation, Common Mental Health Problems, and Infections in People With Inflammatory Bowel Disease
ClinicalTrials.gov study NCT03836612. IPD Sharing: YES. Countries: 1. Publications: 1.
Comparative analysis of Parkinson's and inflammatory bowel disease gut microbiomes reveals shared butyrate-producing bacteria depletion
<p><strong>Abstract: </strong>Epidemiological studies reveal that inflammatory bowel disease (IBD) is associated with an increased risk of Parkinson’s disease (PD). Gut dysbiosis has been documented in both PD and IBD, however it is currently unknown whether gut dysbiosis underlies the epidemiological association between both diseases. To identify shared and distinct features of the PD and IBD microbiome, we recruited 54 PD, 26 IBD, and 16 healthy control individuals and performed the first joint analysis of gut metagenomes. Larger, publicly available PD and IBD metagenomic datasets were also analyzed to validate and extend our findings. Depletions in short-chain fatty acid (SCFA)-producing bacteria, including <em>Roseburia intestinalis, Faecalibacterium prausnitzii, Anaerostipes hadrus</em>, and <em>Eubacterium rectale</em>, as well depletion in SCFA-synthesis pathways were detected across PD and IBD datasets, suggesting that depletion of these microbes in IBD may influence the risk for PD development.</p> <p><strong>Zenodo contents:</strong> In this Zenodo archive we provide the post-QC and taxonomic and functional profiling "Source Data" used in all downstream analyses to generate tables and figures seen in our manuscript. We also provide the link to our GitHub repository where we have stored the code used to perform the bioinformatic processing of the shotgun metagenomic sequences and stastical analyses. Individual sample raw shotgun metagenomic sequences and metadata from our UFPF dataset are available on NCBI Sequence Read Archive (SRA) under BioProject <a href="https://www.ncbi.nlm.nih.gov/bioproject/1096686">PRJNA1096686</a>. </p>
Anti-TNF therapy for inflammatory bowel disease in patients with neurodegenerative Niemann-Pick disease Type C
<p>Abstract:</p> <p>Background: Blockade of tumour necrosis factor (anti-TNF) is effective in patients with Crohn’s Disease but has been associated with infection risk and neurological complications such as demyelination. Niemann-Pick disease Type C1 (NPC1) is a lysosomal storage disorder presenting in childhood with neurological deterioration, liver damage and respiratory infections. Some NPC1 patients develop severe Crohn’s disease. Our objective was to investigate the safety and effectiveness of anti-TNF in NPC1 patients with Crohn’s disease.</p> <p>Methods: Retrospective data on phenotype and therapy response were collected from patients with genetically confirmed NPC1 defects and intestinal inflammation. We investigated TNF secretion in peripheral blood mononuclear cells treated with NPC1 inhibitor in response to bacterial stimuli.</p> <p>Results: NPC1 inhibitor treated PBMCs show significantly increased TNF production after lipopolysaccharide or bacterial challenge providing a rationale for anti-TNF therapy. We identified 5 NPC1 patients with CD-like intestinal inflammation treated using anti-TNF therapy (mean age of onset 8.6 years, mean treatment length 27.2 months, overall treatment period 11.3 patient years). Anti-TNF therapy was associated with reduced gastrointestinal symptoms with no apparent adverse neurological events. Therapy improved intestinal inflammation in 4 patients.</p> <p>Conclusion: Anti-TNF therapy appears safe in patients with NPC1 and is an effective treatment strategy for the management of intestinal inflammation in these patients.</p>
Meta-analysis defines predominant shared microbial responses in various diseases and a specific inflammatory bowel disease signal
<p>Datasets and analysis notebooks for recreating the analysis described in the paper.</p> <p>biom tables of the original datasets used in the meta-analysis are not included due to privacy issues. Instead, we include the biom table containing the NRMD for each study/ASV</p> <p>Updated data and notebooks can also be found at the github page: </p> <p><a href="https://github.com/amnona/paper-metaanalysis">https://github.com/amnona/paper-metaanalysis</a></p> <p>NOTE: files here are provided in a per-directory .zip file in order to preserve internal directory structure.</p> <p> </p>
Inflammatory bowel disease pregnancy and lactation
<p>Inflammatory bowel disease drugs are often immunosupressants for which evidence during pregnancy and lactation needs to be proven. Here you can find up to date data on safety of these drugs.</p> <p>Additional information can be found at www.ibd-eii.com</p>
Timeline of drug development in inflammatory bowel disease
<p>Timeline of drug development in inflammatory bowel disease from the first trial published in 1955 until 2024.</p> <p>Detailed explanation of these trials can be found at www.ibd-eii.com</p>
Patient Attitudes and Preferences for Outcomes of Inflammatory Bowel Disease Therapeutics
ClinicalTrials.gov study NCT02316678. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Acceptability of Identifying and Managing Psychological Distress in Inflammatory Bowel Disease: the COMPASS-IBD Study
ClinicalTrials.gov study NCT05330299. IPD Sharing: YES. Countries: 1. Publications: 1.
Infliximab to Treat Crohn'S-like Inflammatory Bowel Disease in Chronic Granulomatous Disease
ClinicalTrials.gov study NCT00325078. IPD Sharing: Not stated. Countries: 1. Publications: 4.
A Study to Evaluate Disease Control, Treatment Patterns, Burden of Disease and Quality of Life in Participants With Moderate to Severe Inflammatory Bowel Disease (IBD)
ClinicalTrials.gov study NCT03488030. IPD Sharing: YES. Countries: 1. Publications: 1.
Risk of Mental Health Conditions in Children and Young Adults With Inflammatory Bowel Disease and Influence on Health
ClinicalTrials.gov study NCT05206734. IPD Sharing: YES. Countries: 1. Publications: 2.
Improving Outcomes and Reducing Disparities for Patients With Inflammatory Bowel Disease Through Epidemiology and Enhanced Disease Management
ClinicalTrials.gov study NCT06424769. IPD Sharing: YES. Countries: 1. Publications: 11.
Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel Disease
ClinicalTrials.gov study NCT03201445. IPD Sharing: NO. Countries: 11. Publications: 2.
Treatment of Iron Deficiency Anaemia in Inflammatory Bowel Disease With Ferrous Sulphate
ClinicalTrials.gov study NCT01991314. IPD Sharing: NO. Countries: 1. Publications: 1.
Chronotherapy in Inflammatory Bowel Disease
ClinicalTrials.gov study NCT04304950. IPD Sharing: NO. Countries: 1. Publications: 9.
A Self-compassion Intervention for Parents of Children With Inflammatory Bowel Disease (IBD)
ClinicalTrials.gov study NCT04717284. IPD Sharing: YES. Countries: 1. Publications: 3.
Telemedicine To Provide Inflammatory Bowel Disease Outpatient Care
ClinicalTrials.gov study NCT01296841. IPD Sharing: Not stated. Countries: 1. Publications: 7.
Capsule Endoscopy in Inflammatory Bowel Disease (IBD) in Children
ClinicalTrials.gov study NCT02182947. IPD Sharing: NO. Countries: 1. Publications: 20.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.